BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. 2005

Marta Boffito, and David Back, and Meredith Stainsby-Tron, and Andrew Hill, and Giovanni Di Perri, and Graeme Moyle, and Mark Nelson, and Jaqui Tomkins, and Brian Gazzard, and Anton Pozniak
PK Research Ltd., St. Stephen's Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK. marta.boffito@chelwest.nhs.uk

OBJECTIVE To investigate whether the administration of tenofovir diproxil fumarate 300 mg once daily alters the plasma pharmacokinetics of the saquinavir hard gel/ritonavir combination in HIV-1 infected individuals. METHODS On day 1, 12 h pharmacokinetic profiles for saquinavir/ritonavir (1000/100 mg given twice daily) were obtained for 18 subjects. All subjects were receiving ongoing treatment with a saquinavir/ritonavir-containing regimen. Tenofovir diproxil fumarate 300 mg given once daily was then added to the regimen and blood sampling was repeated at days 3 and 14. Saquinavir and ritonavir concentrations were measured by HPLC-MS/MS, and tenofovir concentrations by HPLC with UV detection. RESULTS Following the addition of tenofovir diproxil fumarate to the regimen, saquinavir and ritonavir plasma concentrations were not significantly different compared with day 1. Thus the geometric mean ratios (95% confidence intervals) for the area under the concentration-time curve were 1.16 (0.97, 1.59) and 0.99 (0.87, 1.30) for saquinavir and 1.05 (0.92, 1.28) and 1.08 (0.97, 1.30) for ritonavir, on days 3 and 14, respectively. CONCLUSIONS Tenofovir diproxil fumarate did not alter the pharmacokinetics of saquinavir hard gel/ritonavir.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005782 Gels Colloids with a solid continuous phase and liquid as the dispersed phase; gels may be unstable when, due to temperature or other cause, the solid phase liquefies; the resulting colloid is called a sol.
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068698 Tenofovir An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone. (R)-9-(2-phosphonylmethoxypropyl)adenine,9-(2-Phosphonomethoxypropyl)adenine,9-(2-Phosphonylmethoxypropyl)adenine,9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer,9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098,9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer,9-PMPA (tenofovir),Tenofovir Disoproxil,Tenofovir Disoproxil Fumarate,Viread,Disoproxil Fumarate, Tenofovir,Disoproxil, Tenofovir,Fumarate, Tenofovir Disoproxil
D000225 Adenine A purine base and a fundamental unit of ADENINE NUCLEOTIDES. Vitamin B 4,4, Vitamin B,B 4, Vitamin
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

Marta Boffito, and David Back, and Meredith Stainsby-Tron, and Andrew Hill, and Giovanni Di Perri, and Graeme Moyle, and Mark Nelson, and Jaqui Tomkins, and Brian Gazzard, and Anton Pozniak
Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.
October 2004, The Journal of antimicrobial chemotherapy,
Marta Boffito, and David Back, and Meredith Stainsby-Tron, and Andrew Hill, and Giovanni Di Perri, and Graeme Moyle, and Mark Nelson, and Jaqui Tomkins, and Brian Gazzard, and Anton Pozniak
The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin.
December 2004, Antiviral therapy,
Marta Boffito, and David Back, and Meredith Stainsby-Tron, and Andrew Hill, and Giovanni Di Perri, and Graeme Moyle, and Mark Nelson, and Jaqui Tomkins, and Brian Gazzard, and Anton Pozniak
Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.
April 2003, Journal of acquired immune deficiency syndromes (1999),
Marta Boffito, and David Back, and Meredith Stainsby-Tron, and Andrew Hill, and Giovanni Di Perri, and Graeme Moyle, and Mark Nelson, and Jaqui Tomkins, and Brian Gazzard, and Anton Pozniak
Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg.
December 2004, Antiviral therapy,
Marta Boffito, and David Back, and Meredith Stainsby-Tron, and Andrew Hill, and Giovanni Di Perri, and Graeme Moyle, and Mark Nelson, and Jaqui Tomkins, and Brian Gazzard, and Anton Pozniak
Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
January 2005, Antiviral therapy,
Marta Boffito, and David Back, and Meredith Stainsby-Tron, and Andrew Hill, and Giovanni Di Perri, and Graeme Moyle, and Mark Nelson, and Jaqui Tomkins, and Brian Gazzard, and Anton Pozniak
Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.
August 2001, Journal of acquired immune deficiency syndromes (1999),
Marta Boffito, and David Back, and Meredith Stainsby-Tron, and Andrew Hill, and Giovanni Di Perri, and Graeme Moyle, and Mark Nelson, and Jaqui Tomkins, and Brian Gazzard, and Anton Pozniak
Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women.
December 2011, Therapeutic drug monitoring,
Marta Boffito, and David Back, and Meredith Stainsby-Tron, and Andrew Hill, and Giovanni Di Perri, and Graeme Moyle, and Mark Nelson, and Jaqui Tomkins, and Brian Gazzard, and Anton Pozniak
Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.
January 2008, Antiviral therapy,
Marta Boffito, and David Back, and Meredith Stainsby-Tron, and Andrew Hill, and Giovanni Di Perri, and Graeme Moyle, and Mark Nelson, and Jaqui Tomkins, and Brian Gazzard, and Anton Pozniak
Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers.
January 2005, Antiviral therapy,
Marta Boffito, and David Back, and Meredith Stainsby-Tron, and Andrew Hill, and Giovanni Di Perri, and Graeme Moyle, and Mark Nelson, and Jaqui Tomkins, and Brian Gazzard, and Anton Pozniak
Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.
January 2014, HIV medicine,
Copied contents to your clipboard!